Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Tamgiblimab, an antibody targeting TIGIT.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Sotevtamab, an antibody targeting CLU.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Simridarlimab, an antibody targeting IAP × PD-L1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Rosnilimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Plutavimab, an antibody targeting SARS-CoV-2 Spike RBD.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Peresolimab, an antibody targeting PD-1.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Posdinemab, an antibody targeting Tau.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Quisovalimab, an antibody targeting TNFSF14.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Osemitamab, an antibody targeting Claudin 18.2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Ozuriftamab, an antibody targeting ROR2.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Mupadolimab, an antibody targeting CD73.

Sequence similarity, pairwise alignment, patent-sequence and antibody–antigen evidence for Melredableukin, an antibody targeting Non-Binding.